U.S. markets closed
  • S&P 500

    4,207.27
    -2.97 (-0.07%)
     
  • Dow 30

    33,336.67
    +27.16 (+0.08%)
     
  • Nasdaq

    12,779.91
    -74.89 (-0.58%)
     
  • Russell 2000

    1,975.26
    +6.01 (+0.31%)
     
  • Crude Oil

    94.00
    +2.07 (+2.25%)
     
  • Gold

    1,805.70
    -8.00 (-0.44%)
     
  • Silver

    20.26
    -0.48 (-2.30%)
     
  • EUR/USD

    1.0323
    +0.0021 (+0.21%)
     
  • 10-Yr Bond

    2.8880
    +0.1020 (+3.66%)
     
  • GBP/USD

    1.2201
    -0.0017 (-0.14%)
     
  • USD/JPY

    133.0100
    +0.1370 (+0.10%)
     
  • BTC-USD

    24,203.03
    +358.32 (+1.50%)
     
  • CMC Crypto 200

    573.13
    -1.61 (-0.28%)
     
  • FTSE 100

    7,465.91
    -41.20 (-0.55%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Increasing losses over year doesn't faze investors as stock hikes 31% this past week

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

This month, we saw the Oyster Point Pharma, Inc. (NASDAQ:OYST) up an impressive 74%. But that doesn't change the fact that the returns over the last year have been less than pleasing. After all, the share price is down 46% in the last year, significantly under-performing the market.

While the stock has risen 31% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.

Check out our latest analysis for Oyster Point Pharma

Oyster Point Pharma wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

We doubt Oyster Point Pharma shareholders are happy with the loss of 46% over twelve months. That falls short of the market, which lost 12%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped. Putting aside the last twelve months, it's good to see the share price has rebounded by 33%, in the last ninety days. Let's just hope this isn't the widely-feared 'dead cat bounce' (which would indicate further declines to come). I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Oyster Point Pharma is showing 3 warning signs in our investment analysis , you should know about...

We will like Oyster Point Pharma better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here